Literature DB >> 3017487

Calcium channel inhibitors suppress the morphine-withdrawal syndrome in rats.

F Bongianni, V Carla, F Moroni, D E Pellegrini-Giampietro.   

Abstract

The effects of the Ca2+-channel blockers verapamil and nimodipine, on the behavioural signs of naloxone (1 mg kg-1)-induced abstinence syndrome in morphine-dependent rats, were evaluated. The content of noradrenaline (NA) and of its metabolite 3-methoxy-4-hydroxyphenylglycol (MHPG) was measured, using high performance liquid chromatography and electrochemical detection or gas chromatography-mass spectrometry, in various brain regions of these animals. Possible interactions of nimodipine and verapamil with opioid receptors were evaluated by examining their ability to displace [3H]-naloxone binding to brain membranes. Verapamil (5, 10 and 50 mg kg-1) and nimodipine (1, 5 and 10 mg kg-1) dose-dependently reduced most of the signs of morphine abstinence. Naloxone-precipitated abstinence decreased the NA content in the cortex, hippocampus, brainstem and cerebellum. In the same brain regions the content of MHPG increased, suggesting an increased release of the amine during morphine abstinence. Nimodipine (10 mg kg-1 i.v.) did not change the content of NA or MHPG in the cortex, hippocampus and brainstem. However, nimodipine pre-treatment markedly reduced the changes in NA and MHPG content induced by the abstinence syndrome. Neither verapamil nor nimodipine displaced [3H]-naloxone from its binding sites. These results suggest that Ca2+-channel blockers suppress the behavioural and neurochemical expressions of morphine abstinence by a mechanism that differs from those of opioids or alpha 2-adrenoceptor agonists.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3017487      PMCID: PMC1916987          DOI: 10.1111/j.1476-5381.1986.tb10236.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  28 in total

Review 1.  Nerve cell calcium as a messenger for opiate and endorphin actions.

Authors:  D H Ross; H L Cardenas
Journal:  Adv Biochem Psychopharmacol       Date:  1979

2.  Effects of divalent cations, cation chelators and an ionophore on morphine analgesia and tolerance.

Authors:  R A Harris; H H Loh; E L Way
Journal:  J Pharmacol Exp Ther       Date:  1975-12       Impact factor: 4.030

Review 3.  Commentary: Brain calcium and morphine action.

Authors:  I S Sanghvi; S Gershon
Journal:  Biochem Pharmacol       Date:  1977-07-01       Impact factor: 5.858

4.  A functional correlate for the dihydropyridine binding site in rat brain.

Authors:  D N Middlemiss; M Spedding
Journal:  Nature       Date:  1985 Mar 7-13       Impact factor: 49.962

5.  The effects of divalent ions on morphine analgesia and abstinence syndrome in morphine-tolerant and -dependent mice.

Authors:  H N Bhargava
Journal:  Psychopharmacology (Berl)       Date:  1978-04-28       Impact factor: 4.530

6.  Effects of morphine intoxication on brain catecholamine neurons.

Authors:  L M Gunne; J Jonsson; K Fuxe
Journal:  Eur J Pharmacol       Date:  1969-03       Impact factor: 4.432

7.  Effects of acute and chronic morphine treatments on calcium localization and binding in brain.

Authors:  H Yamamoto; R A Harris; H H Loh; E L Way
Journal:  J Pharmacol Exp Ther       Date:  1978-05       Impact factor: 4.030

8.  On the regulation of gamma-aminobutyric acid neurons in caudatus, pallidus and nigra: effects of opioids and dopamine agonists.

Authors:  F Moroni; E Peralta; D L Cheney; E Costa
Journal:  J Pharmacol Exp Ther       Date:  1979-02       Impact factor: 4.030

9.  Antinociceptive effects of lanthanum and cerium in nontolerant and morphine tolerant-dependent animals.

Authors:  R A Harris; H H Loh; E L Way
Journal:  J Pharmacol Exp Ther       Date:  1976-02       Impact factor: 4.030

10.  Clonidine reversal of increased norepinephrine metabolite levels during morphine withdrawal.

Authors:  J N Crawley; R Laverty; R H Roth
Journal:  Eur J Pharmacol       Date:  1979-08-01       Impact factor: 4.432

View more
  35 in total

1.  Involvement of the cyclic AMP system in the switch from tolerance into supersensitivity to the antinociceptive effect of the opioid sufentanil.

Authors:  M A Hurlé; I Goirigolzarri; E M Valdizán
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

Review 2.  Psychopharmacological properties of calcium channel inhibitors.

Authors:  O Pucilowski
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

3.  Differential effects of L-type calcium channel blockers and stimulants on naloxone-precipitated withdrawal in mice acutely dependent on morphine.

Authors:  M Barrios; J M Baeyens
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

4.  Different mechanisms mediate development and expression of tolerance and dependence for peripheral mu-opioid antinociception in rat.

Authors:  K O Aley; J D Levine
Journal:  J Neurosci       Date:  1997-10-15       Impact factor: 6.167

Review 5.  Calcium antagonists: whither now?

Authors:  W G Nayler
Journal:  Cardiovasc Drugs Ther       Date:  1988-03       Impact factor: 3.727

Review 6.  Novel therapeutic strategies for alcohol and drug addiction: focus on GABA, ion channels and transcranial magnetic stimulation.

Authors:  Giovanni Addolorato; Lorenzo Leggio; F Woodward Hopf; Marco Diana; Antonello Bonci
Journal:  Neuropsychopharmacology       Date:  2011-10-26       Impact factor: 7.853

7.  Reduction of morphine dependence and potentiation of analgesia by chronic co-administration of nifedipine.

Authors:  L Antkiewicz-Michaluk; J Michaluk; I Romańska; J Vetulani
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

8.  Effects of prototypic calcium channel blockers in methadone-maintained humans responding under a naloxone discrimination procedure.

Authors:  Alison Oliveto; Michael Mancino; Nichole Sanders; Christopher Cargile; J Benjamin Guise; Warren Bickel; W Brooks Gentry
Journal:  Eur J Pharmacol       Date:  2013-03-21       Impact factor: 4.432

9.  Concurrent nimodipine attenuates the withdrawal signs and the increase of cerebral dihydropyridine binding after chronic morphine treatment in rats.

Authors:  A Zharkovsky; A M Tötterman; J Moisio; L Ahtee
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-05       Impact factor: 3.000

10.  Effects of trepelennamine on brain monoamine turnover in morphine dependent and abstinent mice.

Authors:  O San-Martin-Clark; B Cuellar; J C Leza; I Lizasoain; P Lorenzo
Journal:  Psychopharmacology (Berl)       Date:  1996-02       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.